Summit X LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

Summit X LLC’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-133	Closed	-$304	–	270
2020 Q3	$304	Buy	+133	New	+$13.5K	0.01%	366

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Summit X LLC's BMRN Position: Q4 2020 in Review

Summit X LLC sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2020, closing a stake of 133 shares — an estimated $304 sold.

Summit X LLC first reported a position in BMRN in Q3 2020 and held it in 1 quarter. The position peaked at $304 in Q3 2020. 537 funds tracked by Wall St. Rank hold BMRN as of Q4 2020.

Summit X LLC reported no remaining BioMarin Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Summit X LLC sold 133 BioMarin Pharmaceuticals shares in Q4 2020, an estimated $304.
Summit X LLC first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 1 quarter.
Summit X LLC's BioMarin Pharmaceuticals position peaked at $304 in Q3 2020.
537 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2020.

Based on Summit X LLC's 13F filing for Q4 2020, filed 29 Jan 2021.